Fertility Preservation in Gynecological Cancer

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Methods and Technologies Development".

Deadline for manuscript submissions: 31 December 2025 | Viewed by 849

Special Issue Editors


E-Mail Website
Guest Editor
Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, Naples, Italy
Interests: oncological gynecology; ovarian cancer; vulvar cancer; endometriosis; PCOS
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

An increasing number of women now postpone reproduction for personal reasons. The risk of developing a gynecologic cancer, including breast cancer, is difficult to estimate in women of reproductive age. Such cancers represent about 10% of all newly diagnosed cancers in this group of women.

Cryopreservation techniques are routinely performed today to store reproductive cells and embryos for many medical or social reasons, including fertility preservation in patients at risk of premature fertility loss, such as patients facing gonadotoxic treatments; women delaying childbearing for personal, professional, financial or psychological reasons; and egg donation programs.

During the last decade, the information and management of fertility issues before oncological treatment have become part of the guidelines that should be considered by all oncological units. However, fertility preservation is an area that needs specific attention and knowledge by dedicated physicians working in this field. Therefore, collaboration between oncological units and fertility clinics is necessary to adequately counsel each patient with a short delay.

Dr. Giuseppe Gullo
Dr. Luigi Della Corte
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • gynecological cancer
  • fertility preservation
  • surgery treatments
  • fertility sparing
  • psychological implication

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

10 pages, 880 KiB  
Article
SIR-EN—New Biomarker for Identifying Patients at Risk of Endometrial Carcinoma in Abnormal Uterine Bleeding at Menopause
by Carlo Ronsini, Irene Iavarone, Maria Giovanna Vastarella, Luigi Della Corte, Giada Andreoli, Giuseppe Bifulco, Luigi Cobellis and Pasquale De Franciscis
Cancers 2024, 16(21), 3567; https://doi.org/10.3390/cancers16213567 - 23 Oct 2024
Viewed by 643
Abstract
Objective: This study aimed to evaluate the efficacy of a new biomarker, termed SIR-En, in identifying patients at risk of endometrial carcinoma among those presenting with abnormal uterine bleeding during menopause. Material and Methods: A retrospective case–control analysis was conducted on 242 women [...] Read more.
Objective: This study aimed to evaluate the efficacy of a new biomarker, termed SIR-En, in identifying patients at risk of endometrial carcinoma among those presenting with abnormal uterine bleeding during menopause. Material and Methods: A retrospective case–control analysis was conducted on 242 women with menopausal abnormal uterine bleeding and endometrial thickness ≥ 4 mm. Peripheral blood samples were collected within 7 days before histological diagnosis. systemic inflammatory reaction (SIR) indices were calculated, including NLR, MLR, PLR, and SII. SIR-En was derived by multiplying SII and endometrial thickness. Statistical analyses, including multivariate linear regression and ROC curve analysis, were performed to assess the diagnostic capability of SIR-En. Results: Patients were categorized into endometrial hyperplasia (50 patients) and endometrial cancer (192 patients) groups. The SIR-En index was significantly higher in the carcinoma group (8710 vs. 6420; p = 0.003). The ROC curve for SIR-En had an AUC of 0.6351 (95% CI: 0.5579–0.7121). Using Youden’s method, the optimal SIR-En cutoff was 13,806, showing a specificity of 0.940 and a positive predictive value of 0.957. Conclusions: Combining systemic inflammatory indices with endometrial thickness, the SIR-En index can effectively distinguish between endometrial hyperplasia and carcinoma in menopausal women with abnormal uterine bleeding. Despite the retrospective design, the identified cutoff’s high specificity and positive predictive value support its potential utility in clinical practice. Further prospective studies are required to validate these findings and optimize clinical application. Full article
(This article belongs to the Special Issue Fertility Preservation in Gynecological Cancer)
Show Figures

Figure 1

Back to TopTop